LOC
Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote
Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile
Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase
Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.
Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China
Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal
CARsgen and Galapagos Resume CAR-T Trials Without Restrictions
CAR-T trials, CARsgen, Galapagos, cancer treatment, clinical trials
Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network
Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals
Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation
Galapagos, investor influence, undervaluation, biotech, corporate control
Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts
Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals
Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case
Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301
Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case
Galapagos, CAR-T cell therapy, Parkinsonism, clinical trial, patient enrollment, BCMA-directed therapy, multiple myeloma
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy